<?xml version="1.0"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/"><rdf:Description rdf:about="https://repozitorij.uni-lj.si/IzpisGradiva.php?id=158261"><dc:title>Clinical application of hempseed or flaxseed oil-based lyotropic liquid crystals</dc:title><dc:creator>Vitek,	Mercedes	(Avtor)
	</dc:creator><dc:creator>Gosenca Matjaž,	Mirjam	(Avtor)
	</dc:creator><dc:subject>lamellar liquid crystals</dc:subject><dc:subject>atopic dermatitis</dc:subject><dc:subject>transepidermal water loss</dc:subject><dc:subject>stratum corneum hydration</dc:subject><dc:subject>erythema index</dc:subject><dc:subject>melanin index</dc:subject><dc:description>The principal function of skin is to form an effective barrier between the human body and its environment. Impaired barrier function represents a precondition for development of skin diseases such as atopic dermatitis (AD), which is the most common inflammatory skin disease characterized by skin barrier dysfunction. AD significantly affects patients' quality of life, thus, there is a growing interest in development of novel delivery systems that would improve therapeutic outcomes. Herein, eight novel lyotropic liquid crystals (LCCs) were investigated for the first time in a double-blind, interventional, before-after, single group trial with healthy adult subjects and twice-daily application regimen. LCCs consisted of constituents with skin regenerative properties and exhibited lamellar microstructure, especially suitable for dermal application. The short- and long-term effects of LCCs on TEWL, SC hydration, erythema index, melanin index, and tolerability were determined and compared with baseline. LCCs with the highest oil content and lecithin/Tween 80 mixture stood out by providing a remarkable 2-fold reduction in TEWL values and showing the most distinctive decrease in skin erythema levels in both the short-and long-term exposure. Therefore, they exhibit great potential for clinical use as novel delivery systems for AD treatment, capable of repairing skin barrier function.</dc:description><dc:date>2024</dc:date><dc:date>2024-05-31 09:57:17</dc:date><dc:type>Članek v reviji</dc:type><dc:identifier>158261</dc:identifier><dc:language>sl</dc:language></rdf:Description></rdf:RDF>
